This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005;23(5):527.

doi: 10.2165/00019053-200523050-00011.

On pharmacogenomics and cost-effectiveness analysis at the individual level

Mohan V Bala, Gary A Zarkin

PMID: 15896103
DOI: 10.2165/00019053-200523050-00011

Comment

On pharmacogenomics and cost-effectiveness analysis at the individual level

Mohan V Bala et al. Pharmacoeconomics. 2005.

. 2005;23(5):527.

doi: 10.2165/00019053-200523050-00011.

Authors

Mohan V Bala, Gary A Zarkin

PMID: 15896103
DOI: 10.2165/00019053-200523050-00011

No abstract available

PubMed Disclaimer

Comment on

Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?
Bala MV, Zarkin GA. Bala MV, et al. Pharmacoeconomics. 2004;22(8):495-8. doi: 10.2165/00019053-200422080-00002. Pharmacoeconomics. 2004. PMID: 15217306

Similar articles

Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?
La Caze A. La Caze A. Pharmacoeconomics. 2005;23(5):445-7. doi: 10.2165/00019053-200523050-00004. Pharmacoeconomics. 2005. PMID: 15896096
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key.
Payne K. Payne K. Pharmacogenomics. 2008 Jan;9(1):1-4. doi: 10.2217/14622416.9.1.1. Pharmacogenomics. 2008. PMID: 18154442 No abstract available.
An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
Phillips KA, Veenstra D, Van Bebber S, Sakowski J. Phillips KA, et al. Pharmacogenomics. 2003 May;4(3):231-9. doi: 10.1517/phgs.4.3.231.22691. Pharmacogenomics. 2003. PMID: 12718713 Review.
Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?
Bala MV, Zarkin GA. Bala MV, et al. Pharmacoeconomics. 2004;22(8):495-8. doi: 10.2165/00019053-200422080-00002. Pharmacoeconomics. 2004. PMID: 15217306
Cost-effectiveness analysis in pharmacogenomics.
Payne K, Shabaruddin FH. Payne K, et al. Pharmacogenomics. 2010 May;11(5):643-6. doi: 10.2217/pgs.10.45. Pharmacogenomics. 2010. PMID: 20415553 Review.

See all similar articles

Cited by

Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.
Bala MV, Mauskopf JA. Bala MV, et al. Pharmacoeconomics. 2006;24(4):345-54. doi: 10.2165/00019053-200624040-00005. Pharmacoeconomics. 2006. PMID: 16605281
Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.
Grutters JP, Sculpher M, Briggs AH, Severens JL, Candel MJ, Stahl JE, De Ruysscher D, Boer A, Ramaekers BL, Joore MA. Grutters JP, et al. Pharmacoeconomics. 2013 Feb;31(2):111-23. doi: 10.1007/s40273-012-0015-4. Pharmacoeconomics. 2013. PMID: 23329430

References

1. J Health Econ. 1996 Jun;15(3):359-68 - PubMed
1. Pharmacoeconomics. 2004;22(8):495-8 - PubMed
1. Pharmacoeconomics. 2005;23(5):445-7 - PubMed
1. N Engl J Med. 1996 May 2;334(18):1174-7 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer